Lyell Immunopharma Net Tangible Assets

Lyell Immunopharma (LYEL) currently reports a net tangible assets of $230M as of June 2026. That compares with $300M in the prior-year period — down 21.8% year over year. Use the charts on this page to explore Lyell Immunopharma's net tangible assets history and peer comparisons.

Lyell Immunopharma's net tangible assets decreased from $300M to $230M — a 21.8% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Lyell Immunopharma reported $230M in net tangible assets as of June 2026. That compares with $300M in the prior-year period — down 21.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net tangible assets of $230M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Lyell Immunopharma, and consider following LYEL for alerts when major investors trade the stock.

Lyell Immunopharma is classified in the Healthcare sector. On net tangible assets, it currently shows $230M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing LYEL with unrelated industries.